FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer.
Nair A, Lemery SJ, Yang J, Marathe A, Zhao L, Zhao H, Jiang X, He K, Ladouceur G, Mitra AK, Zhou L, Fox E, Aungst S, Helms W, Keegan P, Pazdur R.
Nair A, et al. Among authors: yang j.
Clin Cancer Res. 2015 Dec 1;21(23):5205-8. doi: 10.1158/1078-0432.CCR-15-1377. Epub 2015 Aug 31.
Clin Cancer Res. 2015.
PMID: 26324740